Gemcitabine Concurrent with Thoracic Radiotherapy after Induction Chemotherapy with Gemcitabine/Vinorelbine in Locally Advanced Non-Small Cell Lung Cancer

Abstract

After induction chemotherapy, the MTD and frequency of gemcitabine in locally advanced NSCLC is 500 mg/m(2) every 2 weeks during a maximum of 7 weeks of thoracic radiotherapy.

Radiation-induced oesophagitis in lung cancer patients

“…However, their total radiation dose, overall treatment time and MED was in the expected range. The MED, which was according to literature and also in our se- ries highly associated with oesophagitis, was not significantly different between the sequential and concurrent groups [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15]. The incidence and severity of oesophagitis and of neutropenia in the chemoradiation group are also in line with published data [2,3,4,15,19].…”

“…The MED, which was according to literature and also in our se- ries highly associated with oesophagitis, was not significantly different between the sequential and concurrent groups [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15]. The incidence and severity of oesophagitis and of neutropenia in the chemoradiation group are also in line with published data [2,3,4,15,19]. The finding that neutropenia induced by chemotherapy before radiotherapy was not associated with oesophagitis during radiotherapy implies that the correlation between neutropenia and acute oesophagitis during concurrent chemoradiation may be either due to a higher effective bio…”

“…Acute mucositis is one of the main severe toxicities that occur during and early after concurrent chemotherapy and radiotherapy [1,2,3,4,5,6,7]. On average, between 20% and 30% of patients will suffer from grade 3-4 acute oesophagitis, which requires tube or intravenous (i.v.)…”

6-Year Experience of Concurrent Radiochemotherapy with Vinorelbine Plus a Platinum Compound in Multimorbid or Aged Patients with Inoperable Non-Small Cell Lung Cancer

“…Since concurrent RCT leads to a significantly higher rate of side effects, it was concluded that this treatment modality should be reserved only for relatively young patients with few concomitant diseases. In addition to hematotoxicity, the increase in local side effects of radiotherapy (e.g., esophagitis) was a particular problem, even though the intensity of chemotherapy was reduced during irradiation [3,8].Most patients with NSCLC are in poor general health. Our goal was, therefore, to implement a treatment regimen that is practicable in these patients with decreased organ reserve capacity.…”

Radiosensitization Dependent on p53 Function in Bronchial Carcinoma Cells by the Isoflavone Genistein and Estradiol in Vitro*

“…The outcome of curative treatment of inoperable non-small cell lung cancer (NSCLC) is unsatisfactory with low survival and high local failure rates [7,18,22,35]. This is the reason for the urgent search for new therapeutic options in conservative treatment of NSCLC [8,10,12].…”